Ameriprise Financial Inc Affimed N.V. Transaction History

Ameriprise Financial Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $455,991 - $618,140	-82,309 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $427,269 - $626,076	54,919 Added 200.51%	82,309 $700,000
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $9,958 - $16,493	1,945 Added 7.64%	27,390 $217,000
Q4 2020 Feb 12, 2021	SELL	$3.16 - $7.03 $120,933 - $269,038	-38,270 Reduced 60.06%	25,445 $148,000
Q3 2020 Nov 16, 2020	BUY	$3.26 - $4.73 $5,216 - $7,568	1,600 Added 2.58%	63,715 $216,000
Q2 2020 Aug 14, 2020	BUY	$1.58 - $4.63 $61,485 - $180,176	38,915 Added 167.74%	62,115 $287,000
Q1 2020 May 15, 2020	BUY	$1.44 - $3.02 $1,008 - $2,114	700 Added 3.11%	23,200 $37,000
Q4 2019 Feb 14, 2020	SELL	$2.25 - $3.07 $125,100 - $170,692	-55,600 Reduced 71.19%	22,500 $62,000
Q3 2019 Nov 14, 2019	BUY	$2.67 - $3.65 $2,136 - $2,920	800 Added 1.03%	78,100 $230,000
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $72,280 - $117,038	27,800 Added 56.16%	77,300 $222,000
Q1 2019 May 15, 2019	BUY	$3.05 - $4.34 $67,100 - $95,480	22,000 Added 80.0%	49,500 $208,000
Q4 2018 Feb 14, 2019	BUY	$2.82 - $4.67 $77,550 - $128,425	27,500 New	27,500 $86,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.